Bempedoic acid
Esperion
['cardio']
in the clear outcomes trial, bempedoic acid reduced risk for major cv events by 13% vs. placebo, including a 23% lower risk for mi, among adults with a history of cvd or at high risk deemed statin intolerant #acc23 #cardiotwitter 
The content you need, when you need it.